TWTove Wästerlid

Tove Wästerlid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tove Wästerlid has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk factors of clonal hematopoiesis of indeterminate potential

    by Qiaoxue Liu, Fen Yang, Hans-Olov Adami, Yingsuo Zhao, Tove Wästerlid, Fang Fang, Qianwei Liu


  • Open Access

    Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma

    by Zahra Haider, Linn Deleskog Spångberg, Karin E. Smedby, Olha Krynina, Cecilia Jylhä, Irina Savitcheva, Emil Lundin, Marzia Palma, Lotta Hansson, Leonie Saft, et al.

  • Open Access

    Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years

    by Qianwei Liu, Fang Fang, Huiwen Xue, Tove Wästerlid, Karin Ekström Smedby, Xinyuan Liu

    Aplastic anemia (AA) is a bone marrow failure syndrome resulting from the immune destruction of hematopoietic stem cells. Clonal hematopoiesis (CH) is characterized by expansion of progenitor hematopoietic stem cells that harbor leukemogenic driver mutations. It has previously been shown that individuals with AA have a high prevalence of CH. However, the association between CH and AA remains unknown. We conducted a prospective, matched cohort study within the UK Biobank from 2006 to 2022. Individuals with CH were ascertained based on whole-exome sequencing data. For each individual with CH, we randomly selected 10 individuals without CH matched by sex, birth year, and ethnicity from the study population. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) of AA associated with CH using a Cox regression model. We also studied the association by different mutations of CH. We identified 14 471 individuals with CH, and 144 323 matched individuals free of CH. Individuals with CH had a higher risk of AA (HR, 2.72; 95% CI, 2.16-3.43) than the reference group. The increase was greater for individuals with CH mutations in SRSF2 (HR, 19.35; 95% CI, 11.07-33.80), TET2 (HR, 4.45; 95% CI, 3.14-6.29), ASXL1 (HR, 2.06; 95% CI, 1.06-4.00), or DNMT3A (HR, 1.88; 95% CI, 1.31-2.70). In conclusion, CH may precede the diagnosis of AA, particularly in those with SRSF2, TET2, ASXL1, and DNMT3A mutations. Further studies are needed to understand the nature of this association and potential shared pathogenic mechanisms between CH and AA.

  • Association of Pre‐Diagnostic Clonal Hematopoiesis of Indeterminate Potential With Prognosis Among Patients With Cancer

    by Xinyuan Liu, Hans‐Olov Adami, Tove Wästerlid, Huiwen Xue, Maria Feychting, Karin E. Smedby, Fang Fang, Qianwei Liu

    Clonal hematopoiesis of indeterminate potential (CHIP) might impair prognosis of several cancer types. Since previous studies predominantly focused on CHIP after cancer diagnosis, little is known about whether CHIP prior to cancer diagnosis predicts outcome. We performed a prospective cohort study, including 63 486 patients with cancer during 2006 to 2022 in the UK Biobank, to evaluate the association between pre‐diagnostic CHIP and survival of cancer patients. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox regression models. We identified 2860 patients with cancer and pre‐diagnostic CHIP, and 60 626 cancer patients without CHIP. During a median follow‐up of 4.2 years, 1162 patients died in the CHIP group (921 cancer‐specific deaths), and 17 825 in the reference group (14 785 cancer‐specific deaths). Cancer patients with pre‐diagnostic CHIP exhibited a higher rate of overall death (HR 1.18, 95% CI: 1.11–1.25) and cancer‐specific death (HR 1.17, 95% CI: 1.09–1.25) compared with the reference group. A significant association of both overall death and cancer‐specific death was observed for myeloproliferative neoplasms, multiple myeloma, breast cancer, non‐Hodgkin lymphoma, and acute myeloid leukemia/myelodysplastic syndromes. The increased rate of both overall death and cancer‐specific death was noted for CHIP with TET2 , SRSF2 , or JAK2 mutation. These findings suggested extended clinical awareness in cancer patients with pre‐diagnostic CHIP.


  • Clonal hematopoiesis of indeterminate potential and risk of immune thrombocytopenia

    by Qianwei Liu, Tove Wästerlid, Karin E. Smedby, Huiwen Xue, Erik Boberg, Fang Fang, Xinyuan Liu

    Background: Clonal hematopoiesis of indeterminate potential (CHIP) might contribute to the pathogenesis of immune thrombocytopenia (ITP) through immune dysfunction or impairment of megakaryopoiesis and platelet formation. However, little is known about subsequent risk of ITP among individuals with CHIP.Objective: To investigate the risk of ITP among individuals with CHIP.Methods: We investigated the association of CHIP with risk of ITP by a prospective cohort study, including 466,064 participants in the UK Biobank, during 2006 to 2022. CHIP was ascertained based on data of whole exome sequencing. Incident ITP was identified in inpatient hospital records and death register. Cox regression models were utilized to estimate risk of ITP associated with CHIP. We also performed subgroup analyses by CHIP mutations (DNMT3A, TET2, ASXL1, SRSF2, and JAK2).Results: The study included 14,466 and 451,598 individuals with and without CHIP, respectively. We identified 34 and 390 cases of ITP among the CHIP group and the reference group, respectively. CHIP was associated with an increased risk of ITP (hazard ratio [HR] 2.33, 95% confidence interval [CI]: 1.64–3.32). Subgroup analysis revealed that the heightened risk of ITP was greatest in CHIP with JAK2 mutation (HR 54.31, 95% CI: 17.39–169.59), followed by CHIP with SRSF2 (HR 20.11, 95% CI: 8.27–48.87), TET2 (HR 4.00, 95% CI: 2.34–6.83), or DNMT3A (HR 1.95, 95% CI: 1.16–3.27) mutation.Conclusion: CHIP was associated with an increased risk of being diagnosed with ITP, particularly for CHIP with JAK2 or SRSF2 mutation. These findings call for clinical awareness of the risk of ITP among individuals with CHIP.


  • Open Access

    Smart variant filtering - A blueprint solution for massively parallel sequencing-based variant analysis

    by Orlinda Brahimllari, Sandra Eloranta, Patrik Georgii-Hemming, Zahra Haider, Sabine Koch, Aleksandra Krstic, Frantzeska Papadopoulou Skarp, Richard Rosenquist, Karin E Smedby, Fulya Taylan, et al.

    Massively parallel sequencing helps create new knowledge on genes, variants and their association with disease phenotype. This important technological advancement simultaneously makes clinical decision making, using genomic information for cancer patients, more complex. Currently, identifying actionable pathogenic variants with diagnostic, prognostic, or predictive impact requires substantial manual effort. Objective: The purpose is to design a solution for clinical diagnostics of lymphoma, specifically for systematic variant filtering and interpretation. Methods: A scoping review and demonstrations from specialists serve as a basis for a blueprint of a solution for massively parallel sequencing-based genetic diagnostics. Results: The solution uses machine learning methods to facilitate decision making in the diagnostic process. A validation round of interviews with specialists consolidated the blueprint and anchored it across all relevant expert disciplines. The scoping review identified four components of variant filtering solutions: algorithms and Artificial Intelligence (AI) applications, software, bioinformatics pipelines and variant filtering strategies. The blueprint describes the input, the AI model and the interface for dynamic browsing. Conclusion: An AI-augmented system is designed for predicting pathogenic variants. While such a system can be used to classify identified variants, diagnosticians should still evaluate the classification’s accuracy, make corrections when necessary, and ultimately decide which variants are truly pathogenic.

  • Open Access

    Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study

    by Tove Wästerlid, Caroline E. Dietrich, Anna Oksanen, Linn Deleskog Spångberg, Björn E Wahlin, Gunilla Enblad, Per‐Ola Andersson, Eva Kimby, Karin E. Smedby

    Follicular lymphoma (FL) is a clinically heterogeneous disease. The need for treatment, treatment sequencing, number of treatment lines, and its association with survival have not been described in a population‐based setting. We identified all patients diagnosed with FL in the Swedish Lymphoma register from 2007 to 2014, followed until 2020, with detailed data on progression/relapse, transformation, and 2nd and further lines of therapy. During a median follow‐up of 6.8 years, 1226 patients (69%) received 1st systemic treatment, 358 patients (20%) were managed with watch‐and‐wait (WaW) only, and 188 (10%) patients were treated with radiotherapy and did not require additional therapy during the study period. Among patients starting systemic treatment, 496 (40%), 224 (18%), and 88 (7%) received 2nd‐, 3rd‐, or 4th‐line therapy, respectively. The 10‐year cause‐specific cumulative incidence of transformation was 13%. Among patients managed with 1st line R‐single, R‐CHOP, or BR, 54%, 33%, and 29% required 2nd line, respectively. The cumulative probability of starting subsequent treatment within 2 years was 26% after 1st line and 35% after 2nd line treatment. Two‐year OS following 1st, 2nd, 3rd, and 4th line systemic treatment was 84%, 70%, 52%, and 36%, respectively, and remained similar when excluding transformations. We conclude that a substantial proportion of FL patients can be managed with WaW for a long period of time, while patients who require multiple treatment lines constitute a group with a large clinical unmet need. These results constitute valuable real‐world reference data for FL.


  • Open Access

    Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study

    by Sara Ekberg, Daniel Molin, Simon Pahnke, Fanny Bergström, Elsa Brånvall, Karin E. Smedby, Tove Wästerlid

    Background & purpose: The COVID-19 pandemic posed a large challenge for healthcare systems across the world. Comprehensive data on the impact of the COVID-19 pandemic on incidence and mortality in lymphoma are lacking. Patients/methods: Using data from the Swedish lymphoma register, we compare incidence and 1-year survival of lymphoma patients in Sweden before (2017–2019) and during the pandemic (2020 and 2021). Results: Fewer patients were diagnosed with lymphomas during March–June 2020, but the annual incidence rates for 2020 and 2021 were similar to those of 2017–2019. A larger proportion of patients presented with stage IV disease during 2021. There were no differences in other base-line characteristics nor application of active treatment in pre-pandemic and pandemic years. One-year overall survival was not inferior among lymphoma patients during the pandemic years compared to pre-pandemic years i.e., 2017–2019. Interpretation: The COVID-19 pandemic had limited impact on the incidence and mortality of lymphoma in Sweden.


  • Open Access

    Cardiovascular diseases after high‐dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population‐based study

    by Joachim Baech, Simon Husby, Trine Trab, Kristian Kragholm, Peter Brown, Jette S. Gørløv, Judit M. Jørgensen, Sif Gudbrandsdottir, Marianne Tang Severinsen, Kirsten Grønbæk, et al.

    Summary: Cardiovascular diseases, especially congestive heart failure (CHF), are known complications of anthracyclines, but the risk for patients undergoing high‐dose chemotherapy and autologous stem cell transplant (HDT‐ASCT) is not well established. With T‐cell therapies emerging as alternatives, studies of long‐term complications after HDT‐ASCT are warranted. Danish patients treated with HDT‐ASCT for aggressive lymphoma between 2001 and 2017 were matched 1:5 on sex, birth year and Charlson comorbidity score to the general population. Events were captured using nationwide registers. A total of 787 patients treated with HDT‐ASCT were identified. Median follow‐up was 7.6 years. The risk of CHF was significantly increased in the HDT‐ASCT population compared to matched comparators with an adjusted hazard ratio (HR) of 5.5 (3.8–8.1). The 10‐year cumulative incidence of CHF was 8.0% versus 2.0% ( p < 0.001). Male sex, ≥2 lines of therapy, hypertension and cumulative anthracycline dose (≥300 mg/m 2 ) were risk factors for CHF. In a separate cohort of 4089 lymphoma patients, HDT‐ASCT was also significantly associated with increased risk of CHF (adjusted HR of 2.6 [1.8–3.8]) when analysed as a time‐dependent exposure. HDT‐ASCT also increased the risk of other cardiac diseases. These findings are applicable for the benefit/risk assessment of HDT‐ASCT versus novel therapies.